Loading...
XNAS
AVDL
Market cap2.07bUSD
Dec 04, Last price  
21.36USD
1D
-0.02%
1Q
35.50%
Jan 2017
105.53%
Name

Avadel Pharmaceuticals PLC

Chart & Performance

D1W1MN
XNAS:AVDL chart
P/E
—
P/S
12.21
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.53%
Rev. gr., 5y
23.35%
Revenues
169m
+504.79%
23,598,00023,020,00036,654,00038,619,00042,118,00037,094,00032,600,00026,101,00022,443,00014,775,000173,209,000150,246,000172,741,000103,269,00059,215,00022,334,0000027,963,000169,117,000
Net income
-49m
L-69.53%
-27,377,000-35,201,000-37,737,000-12,084,000-11,439,000-8,975,000-8,774,000-3,228,000-42,925,000-84,906,00040,659,000-41,276,00067,254,000-95,304,000-33,226,0007,028,000-77,329,000-137,464,000-160,276,000-48,832,000
CFO
-47m
L-63.50%
-19,389,000-29,826,000-19,241,000-7,508,0008,195,000-5,457,000-10,323,000-23,139,000-20,676,000-10,618,00084,293,00018,901,00016,662,000-82,716,000-38,325,000-48,734,000-77,310,000-70,304,000-128,511,000-46,907,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
URL
https://www.avadel.com/
IPO date
Jan 16, 1952
Employees
41
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT